#MicroRNA #Microbiota #IBD #Immunotherapy #Innovation
Chronic inflammatory bowel diseases (IBD), such as
Crohn's disease and
ulcerative colitis, are characterized by persistent inflammation of the
digestive tract, associated with an imbalance in the gut microbiota. This
dysbiosis, combined with an
exacerbated immune response, contributes to the
chronicity of symptoms and complicates patient management.
Recent research suggests that
fecal microRNAs (miRNAs), particularly
let-7b and miR-21, may play a central role in
regulating interactions between
the host and its gut microbiota. These small regulatory molecules, known for
their
involvement in inflammatory and immune processes, are thought to directly
influence the composition and activity of the gut microbiota. However, the
precise mechanisms by which let-7b and miR-21 modulate microbial balance and
intestinal inflammation remain largely unknown.
This study explores how fecal microRNAs let-7b and miR-21 modulate
host-microbiota interactions, thereby influencing inflammation in IBD.
Read next: Post-Traumatic Stress Disorder, Gut Microbiota, and Inflammation: A Complex Interconnection
MicroRNAs: The Master Regulators of Intestinal Inflammation?
To investigate the influence of microRNAs on gut microbiota and
inflammation in IBD, this study combined in vitro and in vivo
analyses. Fecal samples from patients with IBD were analyzed to identify
microRNAs involved in intestinal inflammation. In parallel, murine models of
chronic colitis (IL-10⁻/⁻ mice) were studied.
The direct influence of let-7b and miR-21 on the composition and
activity of human microbiota was explored using a bacterial culture model
(MiniBioReactor Array). In vivo experiments were conducted on mice,
administering these microRNAs to assess their effects on intestinal barrier
integrity and immune response. Finally, the inhibition of let-7b and miR-21
using anti-miRNAs was tested to evaluate its therapeutic potential in
modulating intestinal inflammation.
The analyses revealed a significant increase in let-7b and miR-21
levels in the stools of IBD patients. In vitro, these microRNAs altered
microbiota composition by promoting the proliferation of pro-inflammatory
bacteria while reducing beneficial populations. In vivo, let-7b
administration induced long-term alterations in gut microbiota and low-grade
chronic inflammation, whereas miR-21 compromised intestinal permeability,
leading to acute inflammation.
Finally, the inhibition of these microRNAs
reduced intestinal
inflammation and i
mproved barrier function, suggesting a potential therapeutic
approach for IBD by directly targeting these molecular regulators.
Towards a New Therapeutic Target for IBD?
IBD, including Crohn’s disease and ulcerative colitis, is characterized
by persistent inflammation and gut microbiota imbalance. Despite
therapeutic advances, managing these diseases remains complex due to variability
in treatment responses and the lack of curative therapies. Identifying new
mechanisms involved in intestinal inflammation is essential for developing
targeted and sustainable therapeutic approaches.
This study aimed to explore the role of fecal microRNAs let-7b and
miR-21 in modulating intestinal inflammation and microbiota composition. By
combining in vitro and in vivo analyses, researchers examined how
these microRNAs influence host-microbiota interactions and assessed the impact
of their inhibition on inflammatory responses.
The results show that let-7b and miR-21 exert distinct yet
complementary effects on intestinal inflammation. Let-7b modifies
microbiota composition and enhances its pro-inflammatory potential, while
miR-21 disrupts the intestinal barrier, promoting more acute
inflammation. Inhibiting these microRNAs significantly reduces inflammation
and improves intestinal integrity, suggesting a new therapeutic approach
for IBD.
This study has certain limitations, including a small patient cohort
and experimental models, requiring validation in larger populations.
Moreover, interactions between microRNAs, the microbiota, and intestinal
immunity remain unclear, necessitating further research before clinical
applications. Future studies should refine microRNA inhibition strategies and
test their effectiveness in clinical trials.
Combined with microbiota-modulating therapies, these approaches
could lead to more targeted and personalized treatments for IBD patients.
Read next: Efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease: a meta-analysis
